Global Blood Therapeutics, Inc. (GBT) Investment Research Dashboard
About Global Blood Therapeutics, Inc. (GBT) stock analysis
Get live GBT stock price $68.49, comprehensive Global Blood Therapeutics, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time GBT stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical firm dedicated to discovering, developing, and providing therapies for patients suffering from sickle cell disease (SCD) who currently lack adequate treatment options. Its marketed product,...
Company Information
- CEO
- Ted Love
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 457
Contact Information
- Website
- https://www.gbt.com
- Address
- 181 OYSTER POINT BLVD
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.46) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Global Blood Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for large-cap equities
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Global Blood Therapeutics, Inc.
- ⚠Investors should consider how Global Blood Therapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
P/E Ratio (TTM)
-14.08
Beta
0.46
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare GBT with peer companies:
- Price
- $64.97+0.00% (1D)
- Market cap
- 4.46B
- Price
- $32.48+0.00% (1D)
- Market cap
- 3.73B
- Price
- $39.95+0.00% (1D)
- Market cap
- 5.51B
- Price
- $18.96+0.00% (1D)
- Market cap
- 11.43B
- Price
- $56.99+0.00% (1D)
- Market cap
- 2.86B
- Price
- $58.70+0.00% (1D)
- Market cap
- 4.12B
- Price
- $26.98+0.00% (1D)
- Market cap
- 2.62B
- Price
- $3.41+0.00% (1D)
- Market cap
- 529.46M
- Price
- $62.49+0.00% (1D)
- Market cap
- 3.75B
- Price
- $46.99+0.00% (1D)
- Market cap
- 3.54B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
- Overall
- —
- NYSE
- —
- NASDAQ
- —
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Communication Services | -0.5% | -1.0% | +3.9% | 21.2 | 68/100⭐⭐⭐⭐ |
| Basic Materials | +0.6% | -0.1% | -0.9% | 24.5 | 32/100⭐⭐ |
| Consumer Cyclical | — | — | — | — | — |
| Consumer Defensive | — | — | — | — | — |
| Energy | — | — | — | — | — |
| Financial Services | — | — | — | — | — |
| Healthcare | — | — | — | — | — |
| Industrials | — | — | — | — | — |
| Real Estate | — | — | — | — | — |
| Technology | — | — | — | — | — |
| Utilities | — | — | — | — | — |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-08-21.